← Research library

Picamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets

Lab research · 2023

What was studied
50 biological targets; computational and in-vitro screening
Main finding
Picamilon showed weak or no binding at 10 μM across the tested panel. This does not exclude other targets, metabolites or effects at other concentrations.

Study data at a glance

Participants or experimental model
50 biological targets; computational and in-vitro screening
Reported results
Picamilon showed weak or no binding at 10 μM across the tested panel. This does not exclude other targets, metabolites or effects at other concentrations.
Study limitations and source details

Study limitations

  • Full methods and risk of bias have not been appraised.
  • These findings do not establish long-term, combination or hazardous-work safety.
  • Related reports may share participants; source records are not independent-trial counts.

Source details

Indexed citation and abstract checked through Europe PMC; full paper not reviewed.

Sources checked

Citation

In vitroEnglish abstract

Santillo MF, Sprando RL. Picamilon, a γ-aminobutyric acid (GABA) analogue and marketed nootropic, is inactive against 50 biological targets Basic & clinical pharmacology & toxicology 132(4). PMID 36668678

Study source ↗ · DOI 10.1111/bcpt.13836 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards